A new Business Roundtable campaign is challenging America's top CEOs to shine a light on how they're doing their part to help improve the health of the environment.
By Johnson & Johnson
For more than 130 years, Johnson & Johnson has made it a mission to help keep people healthy. And since human health and environmental health are inextricably linked, the company is dedicated to helping keep the planet healthy, too.
Acuvue Oasys 1-Day are daily contact lenses designed with HydraLuxe technology for the correction of optical refractive errors associated with ametropic defects in the eye, for both myopia and hyperopia. These lenses were launched using 100% sustainable packaging with paperboard purchased from a Fiber Sourcing Certified plant, and packaging was reduced to one box, compared to the previous packaging of four boxes.
In Lebanon, Johnson & Johnson has partnered with the nongovernmental organization Save the Children to provide refugees displaced by the crisis in Syria with access to early childhood development services.
By Kathryn Wengel, Chief Global Supply Chain Officer for Johnson & Johnson
Is it easy to solve some of the world’s most pressing healthcare challenges? No, but that shouldn’t stop us from trying.
At Johnson & Johnson, we blend heart, science and ingenuity to change the trajectory of health for humanity. This aspiration includes positively impacting patients and consumers, as well as the health of our employees, our communities and the planet. After all, you can’t have healthy people without a healthy planet!
New York, N.Y., October 7, 2015 /3BL Media/– Corporations around the world are banding together with IMPACT 2030 and mobilizing their corporate volunteers to help combat the most critical issues that our world faces, including poverty, inequality and climate change.
By: Michael McCaffrey, Senior Director, Johnson & Johnson Corporate Communication
Innovation is the lifeblood to success for any company competing in the healthcare industry. When it comes to innovation, many healthcare companies have robust, longstanding processes that are highly standardized and easily repeatable over time. However, many of these innovation processes have one shortcoming – they are often front loaded — ie, the bulk of attention is given to idea generation and refinement, with little or no upfront consideration to late stage elements like regulatory strategy, commercialization and access effects. In a rush to market, this lack of for
We’re pleased to share the news that a group of scientists and business leaders from our Janssen team, along with a professor from the Harvard Business School, co-authored a new commentary in the February issue of the journal Nature Reviews Drug Discovery that addresses integrated approaches to healthcare solutions. Husseini Manji, Global Head of Neuroscience at Janssen Research & Development and Michael Yang, President of Janssen Pharmaceuticals, Inc. are two of the Janssen authors.